Clinical trial
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With…
NCT00293423 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00293423 |
|---|---|
| Title | GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma |
| Official title | Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH Agenus Inc. Industry American Brain Tumor Association |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Procedure |
| Interventions | HSPPC-96, Standard Surgical Resection |
| Enrollment | 96 |
| Start date | Nov 18, 2005 |
| Primary completion | Jan 12, 2013 |
| Completion | Jan 12, 2013 |
| First posted | Feb 17, 2006 |
| Last update posted | May 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: